Previous 10 | Next 10 |
2023-07-27 08:56:51 ET Procept press release ( NASDAQ: PRCT ): Q2 GAAP EPS of -$0.56. Revenue of $33.1M (+98.3% Y/Y). For further details see: Procept GAAP EPS of -$0.56, revenue of $33.1M
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the...
2023-07-14 16:23:57 ET Summary EDAP TMS S.A. shares have pushed lower in H2 FY'23, presenting an opportunity to add on weakness. EDAP's Q1 revenues were up 13.8% YoY, with HIFU sales up around 40% YoY. On examination, sentiment and positioning remains bullish in the stock base...
REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report fina...
2023-05-30 10:19:49 ET Summary Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential in urology where its Aquablation technology has many potential indications. The company should re...
2023-04-30 09:31:03 ET Start Time: 08:00 End Time: 08:56 PROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno - President and CEO Kevin Waters - EVP and CFO Matt Bacso - VP, IR...
5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates. The study concluded that Aquablation therapy: ...
2023-04-27 12:52:30 ET Shares of Procept Biorobotics (NASDAQ: PRCT) were down more than 21% as of 12:48 p.m. ET Thursday after the healthcare company released first-quarter earnings before the trading day opened. The stock is now down more than 31% so far this year. Procept ...
2023-04-27 12:08:47 ET For further details see: Procept BioRobotics down 19% on Q1 2023 results
2023-04-27 10:26:14 ET Procept press release ( NASDAQ: PRCT ): Q1 GAAP EPS of -$0.63 misses by $0.05 . Revenue of $24.4M (+71.8% Y/Y) beats by $0.08M . Full Year 2023 Financial Guidance The Company projects revenue for the full year 2023 to be $128 mill...
News, Short Squeeze, Breakout and More Instantly...
PROCEPT BioRobotics Corporation Company Name:
PRCT Stock Symbol:
NASDAQ Market:
PROCEPT BioRobotics Corporation Website:
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial...
SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical A...
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present...